{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:38:17Z","timestamp":1790735897657,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1124\/dmd.120.000068","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T15:54:32Z","timestamp":1593100472000},"page":"788-795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Contribution of Monocarboxylate Transporter 6 to the Pharmacokinetics and Pharmacodynamics of Bumetanide in Mice"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5283-8070","authenticated-orcid":false,"given":"Robert S.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Ruszaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-7964","authenticated-orcid":false,"given":"Marilyn E.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.000068_bib1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2009.03.003","article-title":"Cation-chloride cotransporters and neuronal function","volume":"61","author":"Blaesse","year":"2009","journal-title":"Neuron"},{"key":"10.1124\/dmd.120.000068_bib2","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1523\/JNEUROSCI.0633-10.2010","article-title":"Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy","volume":"30","author":"Brandt","year":"2010","journal-title":"J Neurosci"},{"key":"10.1124\/dmd.120.000068_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ki.1984.153","article-title":"Bumetanide and furosemide in heart failure","volume":"26","author":"Brater","year":"1984","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.120.000068_bib4","doi-asserted-by":"crossref","first-page":"e57148","DOI":"10.1371\/journal.pone.0057148","article-title":"Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures [published correction appears in PLoS One 8]","volume":"8","author":"Cleary","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.120.000068_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/clpt.1988.186","article-title":"Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure","volume":"44","author":"Cook","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.000068_bib6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jps.2600650518","article-title":"Bumetanide: radioimmunoassay and pharmacokinetic profile in humans","volume":"65","author":"Dixon","year":"1976","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.120.000068_bib7","doi-asserted-by":"crossref","first-page":"C846","DOI":"10.1152\/ajpcell.00112.2005","article-title":"Expression and membrane localization of MCT isoforms along the length of the human intestine","volume":"289","author":"Gill","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1124\/dmd.120.000068_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1020521308985","article-title":"The Na-K-Cl cotransporters","volume":"30","author":"Haas","year":"1998","journal-title":"J Bioenerg Biomembr"},{"key":"10.1124\/dmd.120.000068_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/bdd.2510140609","article-title":"Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt induced hypertensive rats","volume":"14","author":"Han","year":"1993","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.120.000068_bib10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1124\/jpet.103.059139","article-title":"Interactions of human organic anion transporters with diuretics","volume":"308","author":"Hasannejad","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.000068_bib11","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/jps.2600730821","article-title":"Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects","volume":"73","author":"Holazo","year":"1984","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.120.000068_bib12","doi-asserted-by":"crossref","unstructured":"Jones RS, Parker MD, Morris AME (2020) Monocarboxylate transporter 6-mediated interactions with prostaglandin F 2\u03b1: in vitro and in vivo evidence utilizing a knockout mouse model, Pharmaceutics 12, p 201.","DOI":"10.3390\/pharmaceutics12030201"},{"key":"10.1124\/dmd.120.000068_bib13","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1021\/acs.molpharmaceut.7b00264","article-title":"Quercetin, morin, luteolin, and phloretin are dietary flavonoid inhibitors of monocarboxylate transporter 6","volume":"14","author":"Jones","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.120.000068_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/mol.119.116731","article-title":"Characterization and proteomic-transcriptomic investigation of monocarboxylate transporter 6 knockout mice: evidence of a potential role in glucose and lipid metabolism","volume":"96","author":"Jones","year":"2019","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.120.000068_bib15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/0883073809333526","article-title":"Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1","volume":"24","author":"Kahle","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1124\/dmd.120.000068_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/bdd.267","article-title":"Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects","volume":"22","author":"Kim","year":"2001","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.120.000068_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1211\/0022357055966","article-title":"Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7])","volume":"57","author":"Kobayashi","year":"2005","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.120.000068_bib18","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1124\/dmd.113.051854","article-title":"Characterization of monocarboxylate transporter 6: expression in human intestine and transport of the antidiabetic drug nateglinide","volume":"41","author":"Kohyama","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000068_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02353407","article-title":"Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments","volume":"22","author":"Lee","year":"1994","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.120.000068_bib20","doi-asserted-by":"crossref","first-page":"R975","DOI":"10.1152\/ajpregu.00693.2005","article-title":"Modulation of single-nephron GFR in the db\/db mouse model of type 2 diabetes mellitus","volume":"290","author":"Levine","year":"2006","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/dmd.120.000068_bib21","doi-asserted-by":"crossref","first-page":"C1496","DOI":"10.1152\/ajpcell.1995.269.6.C1496","article-title":"Distribution and diversity of Na-K-Cl cotransport proteins: a study with monoclonal antibodies","volume":"269","author":"Lytle","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1124\/dmd.120.000068_bib22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1152\/jn.00970.2011","article-title":"Molecular and functional expression of cation-chloride cotransporters in dorsal root ganglion neurons during postnatal maturation","volume":"108","author":"Mao","year":"2012","journal-title":"J Neurophysiol"},{"key":"10.1124\/dmd.120.000068_bib23","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1124\/dmd.105.005264","article-title":"Functional characterization of human monocarboxylate transporter 6 (SLC16A5)","volume":"33","author":"Murakami","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000068_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymeth.2009.12.012","article-title":"Using fluorometry and ion-sensitive microelectrodes to study the functional expression of heterologously-expressed ion channels and transporters in Xenopus oocytes","volume":"51","author":"Musa-Aziz","year":"2010","journal-title":"Methods"},{"key":"10.1124\/dmd.120.000068_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2125.1977.tb00664.x","article-title":"Fate of [14C]-bumetanide in man","volume":"4","author":"Pentik\u00e4inen","year":"1977","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.000068_bib26","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/epi.12620","article-title":"Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures","volume":"55","author":"Puskarjov","year":"2014","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.120.000068_bib27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neuropharm.2017.02.006","article-title":"Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain","volume":"117","author":"R\u00f6mermann","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1124\/dmd.120.000068_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01061766","article-title":"Determinants of bumetanide response in the dog: effect of probenecid","volume":"11","author":"Smith","year":"1983","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.120.000068_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2014.11.019","article-title":"The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide","volume":"746","author":"T\u00f6llner","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.120.000068_bib30","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/ejn.12424","article-title":"Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy","volume":"39","author":"T\u00f6pfer","year":"2014","journal-title":"Eur J Neurosci"},{"key":"10.1124\/dmd.120.000068_bib31","unstructured":"Walmsley L (1985) Pharmacokinetics of Bumetanide, Lorazepam and Clofibric Acid in Cynomolgus Monkeys and Baboons, Loughborough University of Technology."},{"key":"10.1124\/dmd.120.000068_bib32","first-page":"415","article-title":"Pharmacokinetics and metabolism of nateglinide in humans","volume":"29","author":"Weaver","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000068_bib33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/dmd.118.085803","article-title":"Impairment of intestinal monocarboxylate transporter 6 function and expression in diabetic rats induced by combination of high-fat diet and low dose of streptozocin: involvement of butyrate-peroxisome proliferator-activated receptor-\u03b3 activation","volume":"47","author":"Xu","year":"2019","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.000068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:24:47Z","timestamp":1739957087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624078486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0090955624078486"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.000068","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of Monocarboxylate Transporter 6 to the Pharmacokinetics and Pharmacodynamics of Bumetanide in Mice","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.000068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}